Skip to product information
White plastic pill bottle labeled 'TBL150 10 mg, Batch No.002, 02-06-2025' with two white capsules on a beige background – high-resolution supplement product image for pharmaceutical or peptide use
1/2
TBL150(rad150) 100x10mg

TBL150(rad150) 100x10mg

€77,50 EUR
Taxes included.

                                                NOT FOR HUMAN CONSUMPTION

TLB-150 (RAD-150 benzoate) is an investigational, non-steroidal selective androgen receptor modulator (SARM). It is widely described as the benzoate ester analogue of RAD-140 (testolone), engineered to maintain AR selectivity while potentially extending exposure versus the parent scaffold. In vitro vendor data list potent AR modulation in the sub-micromolar range; no approved medical indication or registrational trials exist. medchemexpress.comSports Technology Labs

Additional Benefits of TLB-150 Now Under Investigation

Benefit Key take-aways
1 Duration/steadiness vs RAD-140 The benzoate ester is promoted to prolong active lifespan and smooth concentration–time curves compared with RAD-140; this remains unverified in humans. Sports Technology Labs
2 Muscle anabolism (class effect) As an AR agonist, TLB-150 is positioned to increase fat-free mass and strength similarly to first-gen SARMs—direct human efficacy data for TLB-150 are absent.
3 Bone support (class effect) SARMs up-regulate osteoblast pathways and improve BMD in animals; TLB-150 is presumed comparable pending direct studies.
4 Oral convenience Once-daily oral SARM paradigms favor adherence vs injectables; specific TLB-150 PK in humans is unknown.
5 Potentially lower androgenic “baggage” Like other non-steroidal SARMs, design intent is muscle/bone selectivity with less prostate/skin stimulation than testosterone—needs confirmation.
6 Research-use positioning Commercial listings emphasize research-use only and lack of regulatory approval. medchemexpress.com
7 SARM-class synergy with resistance training Expect additivity with structured training/protein adequacy (extrapolated from SARM literature).
8 Dosing flexibility If ester prolongation holds, lower/fewer doses could yield similar exposure (hypothesis). Sports Technology Labs
9 Doping relevance As a SARM, TLB-150 would be prohibited at all times under WADA S1 (Anabolic Agents). U.S. Anti-Doping Agency (USADA)wada-ama.org

2. Molecular Mechanism of Action

2.1 Receptor Pharmacodynamics

TLB-150 binds the androgen receptor (AR), promoting nuclear translocation and ARE-driven transcription. In muscle, AR activation up-regulates mTOR/S6K and suppresses atrogenes (MAFbx/MuRF1); in bone, AR signaling supports osteoblastogenesis and trabecular integrity (inferred from SARM class biology).

2.2 Down-stream Biology

Pathway Functional outcome Context
AR → mTOR/S6K/4E-BP1 ↑ Protein synthesis, myofiber hypertrophy Skeletal muscle
AR ↔ Wnt/β-catenin/Osterix ↑ Osteoblast activity, ↑ BMD Bone
↓ FoxO/ubiquitin ligases ↓ Proteolysis (anti-catabolic) Catabolic stress
HPG-axis feedback ↓ LH/FSH/testosterone (suppression) Pituitary–gonadal

3. Pharmacokinetics

  • Route: Oral (research use).

  • Design rationale: Benzoate esterification of RAD-140 intended to enhance stability and effective half-life; quantitative human PK is undetermined. Sports Technology Labs

  • Metabolism/clearance: Expected ester hydrolysis → RAD-140-like core + oxidative/conjugative metabolism; formal human data unavailable.

  • Detection: As a SARM, long-term metabolites may extend detection windows in doping control (extrapolated from class).

4. Pre-clinical and Translational Evidence

4.1 Identity & in-vitro profiling

Commercial technical sheets list AR modulation with sub-µM potency and CAS 1208070-53-4; peer-reviewed in-vivoefficacy for TLB-150 specifically is limited/publicly sparse. medchemexpress.com

4.2 Extrapolation from RAD-140/SARM literature

Anabolic FFM gains, strength improvements, and bone protection are well described for earlier SARMs in animals and small human studies; whether TLB-150 surpasses RAD-140 clinically is unknown.

Evidence quality note: TLB-150 data are largely vendor-level and pre-clinical; there are no authoritative human RCTs or approvals.

5. Emerging Clinical Interests

Field Rationale Current status
Sarcopenia/rehab Oral anabolic with putative longer exposure Concept/extrapolation
Osteopenia Bone-anabolic SARM class biology Pre-clinical rationale
Male contraception research Strong HPG suppression is a SARM class effect—unproven for TLB-150 Hypothesis only
Athletics (illicit use) Oral potency + duration = high misuse potential WADA-prohibited U.S. Anti-Doping Agency (USADA)

6. Safety and Tolerability

  • Known/expected class effects:
    HPG-axis suppression (↓ LH/FSH/testosterone), HDL-C reduction (± ↑ LDL/TG), possible ALT/AST elevations, acne/oily skin, mood/insomnia, mild ↑ hematocrit.

  • Unknowns for TLB-150: Human PK, dose–response, long-term hepatic/CV outcomes, neuropsychiatricsignals.

  • Quality risks: Grey-market products show adulteration/mislabeling; use outside trials is unsafe.

  • Drug interactions: Potential hepatic enzyme interactions (class consideration).

  • Pregnancy: Contraindicated (androgenic mechanism).

Comparative safety matrix

Concern TLB-150 (RAD-150) RAD-140 (testolone) Enobosarm (MK-2866)
Oral potency Presumed high (unverified) High (preclinical + forensic) Moderate–high (human Phase 2)
Duration Designed longer (ester) Shorter vs ester ~24 h
Human data None/very limited Limited (non-pivotal) Phase 2 datasets
HDL impact Expected ↓ ↓ ↓
HPG suppression Likely strong Strong Moderate

7. Regulatory Landscape

8. Future Directions

  • Authentic PK/PD: First-in-human GMP studies to define half-life, exposure, metabolite ID, and dose–response.

  • Head-to-head vs RAD-140: Demonstrate superiority (duration/efficacy/safety), not just parity.

  • Long-term safety: Lipids/CV, hepatic, endocrine recovery; standardized monitoring.

  • Doping science: Metabolite mapping and detection windows.

  • Medicinal chemistry: Optimize lipid neutrality and reduced HPG suppression without losing anabolism.

Selected References

  • MedChemExpress technical page: “TLB-150 Benzoate (RAD-150) — AR modulator; CAS 1208070-53-4; research-use only.” medchemexpress.com

  • Vendor/scientific summaries describing RAD-150 as the benzoate ester of RAD-140 with prolonged activity claims. Sports Technology LabsLawless Labs USA

  • USADA: “All SARMs are prohibited at all times (S1 ‘Other Anabolic Agents’).” U.S. Anti-Doping Agency (USADA)

  • WADA Prohibited List (2025) — International Standard.